CHMP recommends Vipidia (Takeda) for Type 2 Diabetes
On 25 July 2013, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Vipidia, from Takeda, 6.25 mg, 12.5 mg and 25 mg, film-coated tablet intended for the treatment of Type 2 Diabetes Mellitus.
The active substance of Vipidia is alogliptin, a dipeptidyl peptidase 4 (DPP 4) inhibitor and oral blood glucose-lowering product (ATC Code A10BH04). DPP-4 inhibition reduces the cleavage and inactivation of the active (intact) form of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), producing an elevation of incretin concentrations that leads to an enhancement of glucose-dependent insulin secretion and a reduction in glucagon release.
Alogliptin is FDA approved as Nesina.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.